A potent and selective inhibitor of protein SUMOylation, a ubiquitin-like post-translational modification, has been developed, shedding light on the potential for developing new classes of anticancer therapeutics.
This is a preview of subscription content, log in via an institution to check access.
References
He, X. et al. Nat. Chem. Biol. 13, 1164–1171 (2017).
Gareau, J.R. & Lima, C.D. Nat. Rev. Mol. Cell Biol. 11, 861–871 (2010).
Geiss-Friedlander, R. & Melchior, F. Nat. Rev. Mol. Cell Biol. 8, 947–956 (2007).
Kessler, J.D. et al. Science 335, 348–353 (2012).
Yu, B. et al. Proc. Natl. Acad. Sci. USA 112, E1724–E1733 (2015).
Brownell, J.E. et al. Mol. Cell 37, 102–111 (2010).
Soucy, T.A. et al. Nature 458, 732–736 (2009).
Demarque, M.D. et al. Gastroenterology 140, 286–296 (2011).
Becker, J. et al. Nat. Struct. Mol. Biol. 20, 525–531 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Schneekloth, J. Controlling protein SUMOylation. Nat Chem Biol 13, 1141–1142 (2017). https://doi.org/10.1038/nchembio.2496
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.2496
- Springer Nature America, Inc.